000 03652nam a22003855i 4500
001 289915
003 MX-SnUAN
005 20160429154728.0
007 cr nn 008mamaa
008 150903s2005 xxu| o |||| 0|eng d
020 _a9781592598663
_99781592598663
024 7 _a10.1385/1592598668
_2doi
035 _avtls000342825
039 9 _a201509030445
_bVLOAD
_c201405070519
_dVLOAD
_y201402061136
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC254-282
100 1 _aAdams, Val R.
_eeditor.
_9320352
245 1 0 _aCamptothecins in Cancer Therapy /
_cedited by Val R. Adams, Thomas G. Burke.
264 1 _aTotowa, NJ :
_bHumana Press,
_c2005.
300 _brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aCancer Drug Discovery and Development
500 _aSpringer eBooks
505 0 _aBiochemistry, Pharmacology, and Chemistry -- Mechanism of Action of Topoisomerase 1 Poisons -- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage -- Inhibitors of Topoisomerase I Function -- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors -- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage -- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs -- Mechanisms of Resistance to Camptothecins -- Recent Advances in Camptothecin Drug Design and Delivery Strategies -- Clinical Perspectives -- Clinical Experience With 9-Aminocamptothecin -- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin) -- Irinotecan -- Clinical Experience With Topotecan -- The Clinical Development of Lurtotecan -- Preclinical and Clinical Development of Exatecan (DX-951f) -- Camptothecins in the Treatment of Primary Brain Tumors -- Camptothecins in the Treatment of Lung Cancer -- Use of Camptothecins in the Treatment of Leukemia and Related Disorders.
520 _aClinical interest in the camptothecins continues to expand even though this class of topoisomerase I inhibitors has been studied for almost 50 years, and two early generation members of the family have gained FDA approval. In Camptothecins in Cancer Therapy, leading clinicians and researchers critically review our current understanding of camptothecins, their shortcomings, and the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance. Authoritative and up-to-date, Camptothecins in Cancer Therapy provides a comprehensive summary of camptothecin research, as well as a much-needed guide to all the latest information on their optimal therapeutic applications.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aBurke, Thomas G.
_eeditor.
_9320353
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9781588290274
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1385/1592598668
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c289915
_d289915